| Ytd | -71.14% | |
| 1y | -75.40% |
| Open | 3.17 | Prev Close | 3.20 | Low | 3.09 | High | 3.24 | Mkt Cap | 38.89M |
| Vol | 43.80K | Avg Vol | 94.75K | EPS | -1.66 | P/E | N/A | Forward P/E | -0.86 |
| Beta | 2.21 | Short Ratio | 1.76 | Inst. Own | 4.13% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-15 | 50-d Avg | 3.32 | 200-d Avg | 4.92 | 1yr Est | 0.00 |
Dallas, Texas--(Newsfile Corp. - October 1, 2026) - Incannex Healthcare Inc. (NASDAQ: IXHL): Stonega
Scilex (NASDAQ: SCLX - Get Free Report) and Incannex Healthcare (NASDAQ: IXHL - Get Free Report) are
Patient dosing commenced in the DReAMzz Phase 2 dose-optimization study of IHL-42X in obstructive sl
First patient dosing represents another major clinical milestone for IHL-42X, building on positive P
Together with the previously announced A$6,039,162.43 refund, Incannex has now received more than A$
First clinical sites approved and actively screening potential participantsRepresents another major
MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasda
Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-m
The granted patent includes claims directed to the proprietary IHL-42X composition and its associate
MELBOURNE, Australia and NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasda
Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-sta
NEW YORK and MELBOURNE, Australia, June 10, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasda
MELBOURNE, Australia and NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasda
Alliance Global Partners analyst James Molloy initiates coverage on Incannex Healthcare (NASDAQ:I
Incannex Healthcare (NASDAQ:IXHL) reported quarterly losses of $(0.35) per share which beat the anal
Major operational milestone achieved as Incannex advances late-stage development of IHL-42X, with al
MELBOURNE, Australia and NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq
Landmark 10th Annual Awards Program Recognizes the Most Innovative Digital Health and Medical Techno
Cronos Group (NASDAQ: CRON - Get Free Report) and Incannex Healthcare (NASDAQ: IXHL - Get Free Repor
Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innova
MELBOURNE, Australia and NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasd
Board initiates buyback activity following period of inactivity, with repurchases executed over the
MELBOURNE, Australia and NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasd
Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing combin
MELBOURNE, Australia and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasd
MELBOURNE, Australia and NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasd
U.S. stocks declined, with Dow Jones falling over 500 points while NASDAQ and S&P 500 also dropp
Incannex Healthcare Limited (NASDAQ: IXHL) shares are tumbling on Thursday as the company announced
Incannex shares drop after announcing a $10 million stock offering to fund its IHL-42X sleep apnea s
U.S. stocks down, Dow falls 500+ points. Energy shares up 0.4%, financial stocks down 1.4%. Jobless
Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innov
Incannex Healthcare Inc. (NASDAQ:IHXL), ("Incannex" or the "Company") a clinical-sta
NEW YORK and MELBOURNE, Australia, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasd
Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innov
Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innova
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for tra